不利影响
附带损害
医学
药品
单克隆抗体
抗体-药物偶联物
食品药品监督管理局
靶向治疗
药物输送
抵押品
免疫疗法
药理学
细胞毒性T细胞
有效载荷(计算)
抗体
癌症研究
肿瘤科
癌症
免疫学
内科学
生物
计算机科学
化学
体外
心理学
有机化学
经济
网络数据包
犯罪学
生物化学
计算机网络
财务
作者
Mohamed A. Gouda,Vivek Subbiah
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2022-11-01
卷期号:28 (6): 496-507
被引量:1
标识
DOI:10.1097/ppo.0000000000000627
摘要
Abstract Antibody-drug conjugates (ADCs) have been revolutionary in improving personalized therapy of cancer. Through combining monoclonal antibodies, which are targeted to tumor-specific antigens, and cytotoxic agents, ADCs lead to selective delivery of active components, also called payloads, to cancerous cells while sparing healthy body cells from possible collateral damage. Adverse events, however, can still develop because of early release of the payload or cross-expression of targets by normal cells leading to collateral damage. In this review, we elaborate on the common and serious adverse events for the currently US Food and Drug Administration–approved ADCs in solid tumors and discuss mitigating strategies and dose modification guidance for optimizing efficacy and toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI